Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma

Launched by QIANFOSHAN HOSPITAL · Dec 21, 2020

Keywords

ClinConnect Summary

This clinical trial is studying whether taking selenium yeast capsules can help improve the outcomes for patients with differentiated thyroid cancer. Researchers believe that selenium, a mineral that the thyroid gland needs, may play a role in protecting the thyroid and possibly even fighting cancer. The trial will look at how selenium supplementation might affect the prognosis of patients who have been diagnosed with this type of cancer and whether it can help prevent the cancer from coming back or spreading.

To be eligible for the study, participants must be between 18 and 75 years old, have been diagnosed with differentiated thyroid cancer after surgery, and must give their consent to participate. Women who can become pregnant need to use contraception during the study. Those with certain health issues, such as severe heart or liver problems, or who are pregnant or breastfeeding, will not be allowed to join. Participants in the study will take selenium yeast capsules and be monitored to see how it affects their health over time. This trial is still in the planning stages and has not yet started recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants have signed informed consent forms；
• • 2. Patients with differentiated thyroid carcinoma diagnosed pathologically after thyroid surgery；
• • 3. Male or female patients aged 18-75 years;
• • 4. Women who are likely to become pregnant must use the appropriate contraceptive method to avoid pregnancy and minimize the likelihood of conception between the beginning of the drug intervention study and the 28th day after the study.
• Exclusion Criteria:
• • 1. A patient who is pregnant or breastfeeding;
• • 2. Currently, hepatase cytochrome P450 3A4 induction or inhibitor therapy, antiviral therapy for immunodeficiency diseases (note: hepatase induction or inhibitor: phenobarbital phenobarbital sodium rifampicin carbamazepine grisoflomycin and dexamethasone and chloramphenicol allopurinol ketone conazole isoniazid imittidine phenothiazine);
• • 3. Gastrointestinal surgery that may affect the study of drug absorption;
• • 4. The patient has a history of haemoglobin disease or acute progressive nephropathy or autoimmune skin disease;
• • 5. A history of substance abuse and alcohol abuse within the last 1 year;
• • 6. There are therapeutic contraindications with selenium yeast capsules as listed in the instructions;
• • 7. New York Heart Association (NYHA) class III or IV congestive heart failure and/or left ventricular ejection fraction of 40% with a significant cardiovascular history in the past 6 months: myocardial infarction coronary angioplasty or bypass surgery valvular disease or repair of unstable angina transient ischemic attack or cerebrovascular accident;
• • 8. There are obvious abnormalities in liver function;
• • 9. The patient has significant liver disease acute active hepatitis or chronic active hepatitis clinical signs or symptoms；
• • 10. Laboratory and physical examination or ECG findings of any clinically significant abnormality would, in the investigator's judgment, compromise the patient's safety or prevent successful participation in the clinical study；
• • 11. Patients with severe renal insufficiency.